Relationship between Cystic Fibrosis with CFTR and a Common Mutation DelF508 with Its Treatment

DOI

10.2991/assehr.k.220701.022How to use a DOI?

Keywords

CFTR; cystic fibrosis; deltaF508; therapy

Abstract

Chronic obstructive pulmonary illness, decreased pancreatic exocrine function, and excessively increased sweat electrolytes are all symptoms of cystic fibrosis, a hereditary exocrine gland disease. The cystic fibrosis gene has a number of mutations. G542X, G551D, Gly542X, Asn1303Lys, and others, for example. The most prevalent cystic fibrosis gene mutation, deltaF508 or F508del, is discussed in this research, as well as how it impacts the cystic fibrosis conductance regulator (CFTR). It will also have an impact on associated treatments like genetic therapy, inhaled antibiotics, dose type, and so on. This paper finds how cystic fibrosis occurs, how delF508 impact human and corresponding treatment (inhaled antibiotics, mucilaginants, and genetic therapies like CRISPER) may help cure the cystic fibrosis.

Copyright

© 2022 The Authors. Published by Atlantis Press SARL.

Open Access

This is an open access article distributed under the CC BY-NC 4.0 license.

Download article (PDF)

TY  - CONF
AU  - Yilan Ling
PY  - 2022
DA  - 2022/07/04
TI  - Relationship between Cystic Fibrosis with CFTR and a Common Mutation DelF508 with Its Treatment
BT  - Proceedings of the 2022 International Conference on Science and Technology Ethics and Human Future (STEHF 2022)
PB  - Atlantis Press
SP  - 109
EP  - 112
SN  - 2352-5398
UR  - https://doi.org/10.2991/assehr.k.220701.022
DO  - 10.2991/assehr.k.220701.022
ID  - Ling2022
ER  -